Pfizer says variant first found in South Africa could significantly reduce vaccine protection

METRO PLUS

Many feared dead as explosion rocks Benue community [PHOTOS]

Scores have been reportedly killed in a fuel tanker explosion at the Amoke village of Apa Local Government Area in Benue State.

Osun: One dead, children, others injured as masquerades attack Muslims

At least, one person has been confirmed dead while about 12 persons, including children sustained gunshot injuries in a clash that ensued...

4 confirmed dead after car hit six pedestrians in Yola

Four pedestrians have been confirmed dead and two others injured after a car hit them around the Adamawa State capital, Yola.

Two rescued, 12 abducted in Kaduna community

Kaduna Police Command has rescued two persons, while 12 others were abducted by bandits in Kachia local government area of Kaduna State.

Man sets in-law’s house ablaze in Jigawa

A 40-year-old man, Ibrahim Musa has set his in-law’s house ablaze at Kuzoyara village, Birniwa local Government area of Jigawa State.

A laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from the Pfizer Inc/BioNTech SE vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday.

The study found the vaccine was still able to neutralize the virus and there is not yet evidence from trials in people that the variant reduces vaccine protection, the companies said.

Still, they are making investments and talking to regulators about developing an updated version of their mRNA vaccine or a booster shot, if needed.

For the study, scientists from the companies and the University of Texas Medical Branch (UTMB) developed an engineered virus that contained the same mutations carried on the spike portion of the highly contagious coronavirus variant first discovered in South Africa, known as B.1.351. The spike, used by the virus to enter human cells, is the primary target of many COVID-19 vaccines.

Researchers tested the engineered virus against blood taken from people who had been given the vaccine, and found a two- thirds reduction in the level of neutralizing antibodies compared with its effect on the most common version of the virus prevalent in U.S. trials.

Their findings were published in the New England Journal of Medicine (NEJM).

Because there is no established benchmark yet to determine what level of antibodies are needed to protect against the virus, it is unclear whether that two-thirds reduction will render the vaccine ineffective against the variant spreading around the world.

However, UTMB professor and study co-author Pei-Yong Shi said he believes the Pfizer vaccine will likely be protective against the variant.

“We don’t know what the minimum neutralizing number is. We don’t have that cutoff line,” he said, adding that he suspects the immune response observed is likely to be significantly above where it needs to be to provide protection.

That is because in clinical trials, both the Pfizer/BioNTech vaccine and a similar shot from Moderna Inc conferred some protection after a single dose with an antibody response lower than the reduced levels caused by the South African variant in the laboratory study.

Even if the concerning variant significantly reduces effectiveness, the vaccine should still help protect against severe disease and death, he noted. Health experts have said that is the most important factor in keeping stretched healthcare systems from becoming overwhelmed.

More work is needed to understand whether the vaccine works against the South African variant, Shi said, including clinical trials and the development of correlates of protection – the benchmarks to determine what antibody levels are protective.

Pfizer and BioNTech said they were doing similar lab work to understand whether their vaccine is effective against another variant first found in Brazil.

Moderna published a correspondence in NEJM on Wednesday with similar data previously disclosed elsewhere that showed a sixfold drop antibody levels versus the South African variant.

Moderna also said the actual efficacy of its vaccine against the South African variant is yet to be determined. The company has previously said it believes the vaccine will work against the variant.

Source: CTV NEWS

Sign up to FREE email alerts from Tribunepoint Weekly - Daily News

When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.

- Advertisement -

Read Also

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest News

Anambra 2021: Soludo remains APGA Guber candidate – Ex-CBN boss’ spokesman, Pauly Onyeka insists

The camp of former Central Bank of Nigeria, CBN, Governor Prof. Charles Soludo, has rubbished the recent court orders declaring Chuma Umeoji...

Kwara APC crisis: Parallel congresses imminent on Saturday

There are strong indications that parallel congresses will be held by the two major warring factions of the All Progressives Congress in...

Man City to get £10m from Sancho’s transfer to Manchester United

Manchester City will earn around £10 million following Jadon Sancho’s move from Borussia Dortmund to their rivals Manchester United.

We don’t rig elections, Nigerians trust us – APC replies PDP

The All Progressives Congress (APC) has rejected the allegation of planned rigging in 2023 made by National Chairman of the Peoples Democratic...

UK govt meets FG over Nnamdi Kanu’s rearrest, pledges to assist IPOB leader

The British High Commission has said it will engage the Nigerian Government over the rearrest of Nnamdi Kanu, leader of the Indigenous...